Business Wire08.13.20
Paragonix Technologies Inc. a commercial stage company and leader in organ preservation and transport technology, announced that Alexander K. Arrow, M.D., CFA has joined its Board of Directors.
Dr. Arrow is a medical technology executive with 24 years of experience in management and finance roles at small and medium-size companies. He is the CEO of Zelegent Inc., which develops, manufactures, and sells minimally-invasive tools for otolaryngologists. He is also the chief financial officer (CFO) of Carlsmed Inc., a spinal implant manufacturer, and Protagenic Therapeutics Inc., a biotechnology company developing neuro-active peptides. He previously served as the president and chief operating officer of Biolase Inc., and the CFO of Arstasis Inc., a cardiovascular device manufacturer. Before his operating roles, Dr. Arrow spent nine years in equity research at three Wall Street firms, the last five years as the head of med tech research at Lazard Ltd.
Bill Edelman, board chairman and CEO, noted, “We are thrilled to have Dr. Arrow join the Paragonix Board, who brings a truly unique perspective with his background as a physician, financial analyst, and life sciences corporate leader. Very few individuals have led this industry from so many vantage points, and we look forward to Dr. Arrow’s contribution to the continued growth of Paragonix as a market leader in transplantation. With the addition of Dr. Arrow to the Board, we note the retirement of Charles Hanor, who we thank for his contribution to the board.”
“Some medical devices are incremental improvements compared to the standard of care, while others are leaps forward that make a measurable difference in patient outcomes,” said Dr. Arrow. “I prefer to be involved with the latter—with devices that inspire us and generate enthusiasm from all who see them. That’s why I’m happy to be joining the board of Paragonix."
Dr. Arrow is a medical technology executive with 24 years of experience in management and finance roles at small and medium-size companies. He is the CEO of Zelegent Inc., which develops, manufactures, and sells minimally-invasive tools for otolaryngologists. He is also the chief financial officer (CFO) of Carlsmed Inc., a spinal implant manufacturer, and Protagenic Therapeutics Inc., a biotechnology company developing neuro-active peptides. He previously served as the president and chief operating officer of Biolase Inc., and the CFO of Arstasis Inc., a cardiovascular device manufacturer. Before his operating roles, Dr. Arrow spent nine years in equity research at three Wall Street firms, the last five years as the head of med tech research at Lazard Ltd.
Bill Edelman, board chairman and CEO, noted, “We are thrilled to have Dr. Arrow join the Paragonix Board, who brings a truly unique perspective with his background as a physician, financial analyst, and life sciences corporate leader. Very few individuals have led this industry from so many vantage points, and we look forward to Dr. Arrow’s contribution to the continued growth of Paragonix as a market leader in transplantation. With the addition of Dr. Arrow to the Board, we note the retirement of Charles Hanor, who we thank for his contribution to the board.”
“Some medical devices are incremental improvements compared to the standard of care, while others are leaps forward that make a measurable difference in patient outcomes,” said Dr. Arrow. “I prefer to be involved with the latter—with devices that inspire us and generate enthusiasm from all who see them. That’s why I’m happy to be joining the board of Paragonix."
